Journal List > Tuberc Respir Dis > v.63(4) > 1001151

TOOLS
Hwang, Park, Kwon, Yoon, Lee, Han, Shim, and Lee: Correlation Between NT-proBNP and Pulmonary Arterial Pressure in COPD Patients
Original Article
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2007; 63(4): 346-352.

Published online: 31 October 2007

DOI: https://doi.org/10.4046/trd.2007.63.4.346

Correlation Between NT-proBNP and Pulmonary Arterial Pressure in COPD Patients

Yong Il Hwang, M.D.1, Geun Min Park, M.D.1, Sung Youn Kwon, M.D.1, 2, Ho Il Yoon, M.D.1, 2, Choon-Taek Lee, M.D.1, 2, Sung Koo Han, M.D.1, Young Soo Shim, M.D.1, Jae Ho Lee, M.D.1, 2

1Department of Internal Medicine, Seoul National University, College of Medicine, Lung Institute of Seoul National University Medical Research Center, Seoul, Korea.

2Medicine and Respiratory Center, Seoul National University Bundang Hospital, Seongnam, Korea.

Address for correspondence: Jae Ho Lee, M.D. Medicine and respiratory center, Seoul National University Bundang Hospital, 300 Goomi-dong, Bundang-gu, Seongnam, Gyeonggi, 463-707, Korea. Phone: 82-31-787-7011, Fax: 82-31-787-4052, jhlee7@snubh.org

Received 14 June 2007       Accepted 24 October 2007

Copyright © 2007 The Korean Academy of Tuberculosis and Respiratory Diseases

Abstract

Background

Pulmonary hypertension is one of the cardiovascular complications of in COPD. However, a diagnosis of pulmonary hypertension requires an invasive test, such as right heart catheterization. NT-proBNP is a cardiac hormone that is elevated when a cardiac volume or pressure overload is present. It was hypothesized that NT-proBNP might play a role in detecting of pulmonary hypertension in COPD patients.

Method

The 31 COPD patients, who underwent all of NT-proBNP, echocardiography, and spirometry in Seoul National University Bundang Hospital during the period from November 2003 to July 2005, were retrospectively analyzed.

Result

Of the 31 COPD patients, 9 patients had pulmonary hypertension. A significant positive correlation was observed between the NT-proBNP and pulmonary arterial pressure (r=0.589, p=0.002). However, there was no significant correlation observed between the FEV1 and NT-proBNP and FEV1 and pulmonary arterial pressure.

Conclusion

NT-proBNP might indicate the presence of pulmonary hypertension in COPD patients.

Keywords: Chronic obstructive pulmonary disease, Pulmonary hypertension, Natriuretic peptide, NT-proBNP

Figures and Tables

Figure 1
Correlation of NT- proBNP and pulmonary arterial pressure.
trd-63-346-g001
Figure 2
ROC curve.
trd-63-346-g002
Table 1
Baseline characteristics of the patients
trd-63-346-i001
Table 2
NT-proBNP, PAP according to the GOLD stage
trd-63-346-i002

PAP: Pulmonary Arterial Pressure; PH: pulmonary Hypertension.

*p > 0.05.

Table 3
NT-proBNP, PAP according to the FEV1 level
trd-63-346-i003

PAP: Pulmonary Arterial Pressure; PH: pulmonary Hypertension.

*p > 0.05.

Table 4
Correlation of FEV1 and NT-proBNP, pulmonary arterial pressure
trd-63-346-i004

r: Pearson's correlation coefficient.

All p > 0.05.

Table 5
NT-proBNP, FEV1 vs. pulmonary hypertension
trd-63-346-i005

*p=0.013.

References

1. National Heart, Lung, and Blood Institute and World Health Organization. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute, National Institutes of Health. [revised 2006]. Bethesda, MD, USA: Available from: http://www.goldcopd.com.
2. Kim DS, Kim YS, Jung K-S, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea. Am J Respir Crit Care Med. 2005. 172:842–847.
3. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003. 21:347–360.
4. Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc Am Thorac Soc. 2005. 2:12–19.
5. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005. 2:20–22.
6. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003. 21:892–905.
7. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care. 2001. 5:286–289.
8. Weitzenblum E, Chaouat A. Severe pulmonary hypertension in COPD: is it a distinct disease? Chest. 2005. 127:1480–1482.
9. Lee-Chiong TL Jr, Matthay RA. Pulmonary hypertension and cor pulmonale in COPD. Semin Respir Crit Care Med. 2003. 24:263–272.
10. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003. 167:735–740.
11. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001. 164:219–224.
12. Bossone E, Bodini BD, Mazza A, Allegra L. Pulmonary arterial hypertension: the key role of echocardiography. Chest. 2005. 127:1836–1843.
13. Kim NH. Diagnosis and evaluation of patient with pulmonary hypertension. Cardiol Clin. 2004. 22:367–373.
14. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and right heart. Chest. 2004. 126:1330–1336.
15. Ruskoaho H. Caridac hormones as diagnostic tools in heart failure. Endocr Rev. 2003. 24:341–356.
16. Clerico A, Emdin M. Diagnostic accuracy and prognostic relavance of measurement of cardiac natriuretic peptides: a review. Clin Chem. 2004. 50:33–50.
17. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary arterial systolic pressure among echocardiographically normal subjects. Circulation. 2001. 104:2797–2802.
18. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004. 43:40S–47S.
19. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003. 46:28S–32S.
20. Chaouat A, Bugnet A, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe pulmoanry hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005. 172:189–194.
21. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. National Emphysema Treatment Trial (NETT) Research Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002. 166:314–322.
22. Mitchell RS, Vincent TN, Ryan S, Filley GF. Chronic obstructive bronchopulmonary disease, IV: The clinical and physiological difference of chronic bronchitis and emphysema. Am J Med Sci. 1964. 247:513–517.
23. Renzetti AD Jr, McClement JH, Litt BD. The Veterans Administration cooperative study of pulmonary function, 3. Mortality in relation to respiratory function in chronic obstructive pulmonary disease. Am J Med. 1966. 41:115–129.
24. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000. 102:865–870.
25. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med. 1999. 93:507–514.
26. Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta. 2000. 301:19–30.
27. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natiruretic peptide levels increase in proportion to extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998. 31:202–208.
28. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med. 2003. 114:266–270.
TOOLS
Similar articles